Cardiotoxicidade induzida por trastuzumabe em pacientes com câncer de mama HER-2 positivo
DOI:
https://doi.org/10.33448/rsd-v11i15.36597Palavras-chave:
Neoplasia da mama; Trastuzumabe; Cardiotoxicidade; Oncologia.Resumo
Introduction: Trastuzumab is a humanized monoclonal antibody precursor of HER-2 positive inhibitors. Cardiotoxicity is one of the most important adverse reactions from a clinical point of view, associated with trastuzumab use. Studies show that 12.6% of patients treated with the HER-2 inhibitor had cardiotoxicity. Objective: To identify the presence of trastuzumab-induced cardiotoxicity in patients with HER-2 positive breast cancer. Method: The study was cross-sectional and retrospective, carried out in a philanthropic cancer hospital in the city of Salvador, Bahia, Brazil. Data were collected through electronic medical records. Patients with a diagnosis of HER-2 positive breast cancer, female, over 18 years of age, who used trastuzumab from September to December 2020, were included in the study. The variables analyzed were: age, comorbidity, combination of chemotherapy (monotherapy, associated) and type of therapy (adjuvant, neoadjuvant). Results: 159 patients were included in the study. 10 (6%) of them had cardiotoxicity during treatment, most of them aged between 40-59 years (70%). Regarding comorbidities, 6 (60%) patients were hypertensive. 7 of the patients (70%) were on trastuzumab monotherapy. All patients use transtuzumab as an adjuvant treatment. Conclusion: In the present study, it was possible to identify the presence of cardiotoxicity in patients who used trastuzumab. Thus, it is essential to pay special attention to the monitoring of cardiac function, as well as the clinical follow-up of these patients to identify, early on, signs and symptoms presented and thus prevent possible damage. In future research, new monitoring parameters should be studied to identify trastuzumab-induced cardiotoxicity early.
Referências
Adão, R., De Keulenaer, G., Leite-Moreira, A., & Braś-Silva, C. (2013). Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention strategies. Revista Portuguesa de Cardiologia, 32(5), 395–409. https://doi.org/10.1016/J.REPC.2012.11.002
Arias, V. E. A., Gobbi, H., Ioshii, S. O., Scapulatempo, C., Da Paz, A. R., Da Silva, V. D., Uchôa, D., Zettler, C., & Soares, F. A. (2017). Assessment of HER-2 status in invasive breast cancer in Brazil. Revista Da Associacao Medica Brasileira, 63(7), 566–574. https://doi.org/10.1590/1806-9282.63.07.566
Barron, C. C., Alhussein, M. M., Kaur, U., Cosman, T. L., Tyagi, N. K., Brown, M., Mukherjee, S. D., Ellis, P. M., Dhesy-Thind, S., & Leong, D. P. (2019). An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction. Current Oncology, 26(4), 240–246. https://doi.org/10.3747/co.26.4631
Bradley, R., Braybrooke, J., Gray, R., Hills, R., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., Taylor, C., Anderson, S., Gelber, R., Gianni, L., Jacot, W., Joensuu, H., Moreno-Aspitia, A., Piccart, M., Press, M., … Swain, S. M. (2021). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. The Lancet. Oncology, 22(8), 1139–1150. https://doi.org/10.1016/S1470-2045(21)00288-6
Buzatto, I. P. C., Ribeiro-Silva, A., Andrade, J. M., Carrara, H. H. A., Silveira, W. A., & Tiezzi, D. G. (2017). Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Brazilian Journal of Medical and Biological Research, 50(2). https://doi.org/10.1590/1414-431X20165674
Curigliano, G., De Azambuja, E., Lenihan, D., Calabrò, M. G., Cardinale, D., & Cipolla, C. M. (2019). Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. The Oncologist, 24(11), e1034–e1043. https://doi.org/10.1634/THEONCOLOGIST.2018-0773
Do, M., Ferreira, C., Bhadra, D., Ii, V., Berti De Azevedo, M., & Iii, B. (2021). Incidência e mortalidade por câncer de mama e do colo do útero em um município brasileiro. https://doi.org/10.11606/s1518-8787.2021055003085
DuMond, B., Patel, V., Gross, A., Fung, A., & Weber, S. (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach. Journal of Oncology Pharmacy Practice, 27(5), 1214–1221. https://doi.org/10.1177/1078155221999712
Eiger, D., Franzoi, M. A., Pondé, N., Brandão, M., De Angelis, C., Schmitt Nogueira, M., De Hemptinne, Q., & De Azambuja, E. (2020). Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. ESMO Open, 5(1). https://doi.org/10.1136/ESMOOPEN-2019-000659
El-Sherbeny, W. S., Sabry, N. M., & Sharbay, R. M. (2019). Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy. Journal of Echocardiography, 17(2), 76–83. https://doi.org/10.1007/S12574-018-0394-4
Esteva, F. J., Baranau, Y. V., Baryash, V., Manikhas, A., Moiseyenko, V., Dzagnidze, G., Zhavrid, E., Boliukh, D., Stroyakovskiy, D., Pikiel, J., Eniu, A. E., Li, R. K., Rusyn, A. V., Tiangco, B., Lee, S. J., Lee, S. Y., Yu, S. Y., & Stebbing, J. (2019). Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial. Cancer Chemotherapy and Pharmacology, 84(4), 839–847. https://doi.org/10.1007/s00280-019-03920-4
Florido, R., Smith, K. L., Cuomo, K. K., & Russell, S. D. (2017). Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. Journal of the American Heart Association, 6(9). https://doi.org/10.1161/JAHA.117.006915
Gabani, M., Castañeda, D., Nguyen, Q. M., Choi, S.-K., Chen, C., Mapara, A., Kassan, A., Gonzalez, A. A., Khataei, T., Ait-Aissa, K., & Kassan, M. (2021). Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy. Cureus, 13(9), e18194. https://doi.org/10.7759/CUREUS.18194
Geralda, P., De, M., Silva, P., Galdino De Paula, V., Ferreira De Almeida, L., Carvalho, E. C., Silva, S., Soares, S., Valéria, N., De, D., Souza, O., Regina, S., Pereira, M., Biancha, K., & De Andrade, S. (2021). Cardiotoxicity associated with oncological chemotherapy: Identification of risk factors. Research, Society and Development, 10(2), e9110212299–e9110212299. https://doi.org/10.33448/RSD-V10I2.12299
Koulaouzidis, G., Yung, A. E., Yung, D. E., Skonieczna-Żydecka, K., Marlicz, W., Koulaouzidis, A., & Charisopoulou, D. (2021). Conventional cardiac risk factors associated with trastuzumab-induced cardiotoxicity in breast cancer: Systematic review and meta-analysis. Current Problems in Cancer, 45(5). https://doi.org/10.1016/J.CURRPROBLCANCER.2021.100723
Mohan, N., Jiang, J., Dokmanovic, M., & Wu, W. J. (2018). Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antibody Therapeutics, 1(1), 13–17. https://doi.org/10.1093/ABT/TBY003
Negishi, T., Thavendiranathan, P., Negishi, K., Marwick, T. H., Aakhus, S., Murbræch, K., Massey, R., Bansal, M., Fukuda, N., Hristova, K., Izumo, M., La Gerche, A., Costello, B., Lemieux, J., Coté, M. A., Deblois, J., Mottram, P., Miyazaki, S., Nolan, M., … Santoro, C. (2018). Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial. JACC: Cardiovascular Imaging, 11(8), 1098–1105. https://doi.org/10.1016/J.JCMG.2018.03.019
Nemeth, B. T., Varga, Z. V., Wu, W. J., & Pacher, P. (2017). Trastuzumab cardiotoxicity: from clinical trials to experimental studies. British Journal of Pharmacology, 174(21), 3727–3748. https://doi.org/10.1111/BPH.13643
Oikonomou, E. K., Kokkinidis, D. G., Kampaktsis, P. N., Amir, E. A., Marwick, T. H., Gupta, D., & Thavendiranathan, P. (2019). Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. JAMA Cardiology, 4(10), 1007–1018. https://doi.org/10.1001/JAMACARDIO.2019.2952
Pereira Vaz, J., Nogueira Da Silva, A. H., Luiz, P., Navarro, B., & Errante, P. R. (2016). Diminuição da fração de ejeção do ventrículo esquerdo (FEVE) pelo uso do Trastuzumabe em pacientes com de câncer de mama HER2 positivo. Revista de Ciências Médicas e Biológicas, 15(2), 165–171. https://doi.org/10.9771/CMBIO.V15I2.16866
Piccart, M., Procter, M., Fumagalli, D., De Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., Bonnefoi, H., Krop, I., Liu, T. W., kowski, T. P., Toi, M., Wilcken, N., Andersson, M., Im, Y. H., Tseng, L. M., … Thomssen, C. (2021). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years’ Follow-Up. Journal of Clinical Oncology, 39(13), 1448–1457. https://doi.org/10.1200/JCO.20.01204
Pina, L. C. de O., Axelband, F., Barbosa, M. F., & Silva, M. J. S. da. (2019). Cardiotoxicidade nas Terapias Neoadjuvante e Adjuvante do Câncer de Mama. Revista Brasileira de Cancerologia, 65(3). https://doi.org/10.32635/2176-9745.rbc.2019v65n3.404
Seferina, S. C., De Boer, M., Wouter Derksen, M., Van Den Berkmortel, F., Van Kampen, R. J. W., Agn`, A., Van De Wouw, A. J., Joore, M., Peer, P. G. M., Voogd, A. C., & Tjan-Heijnen, V. C. G. (2016). Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium. https://doi.org/10.1634/theoncologist.2015-0230
Siddiqui, M. U., Yaacoub, Y., Hanson, H. A., Junarta, J., Pasha, A. K., & Shah, M. (2022). Echocardiographic predictors of symptomatic cardiotoxicity among patients undergoing chemotherapy: A systematic review and meta-analysis. Medicine, 101(28), E29562. https://doi.org/10.1097/MD.0000000000029562
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., Pinter, T., Valero, V., Liu, M.-C., Sauter, G., von Minckwitz, G., Visco, F., Bee, V., Buyse, M., Bendahmane, B., … Crown, J. (2011). Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine, 365(14), 1273–1283. https://doi.org/10.1056/NEJMOA0910383
Tang, G. H., Acuna, S. A., Sevick, L., Yan, A. T., & Brezden-Masley, C. (2017). Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single “real-world” setting. Medical Oncology (Northwood, London, England), 34(9). https://doi.org/10.1007/S12032-017-1018-Y
Tsang, J. Y. S., & Tse, G. M. (2020). Molecular Classification of Breast Cancer. Advances in Anatomic Pathology, 27(1), 27–35. https://doi.org/10.1097/PAP.0000000000000232
Yang, H., Bhoo-Pathy, N., Brand, J. S., Hedayati, E., Grassmann, F., Zeng, E., Bergh, J., Bian, W., Ludvigsson, J. F., Hall, P., & Czene, K. (2022). Risk of heart disease following treatment for breast cancer - results from a population-based cohort study. ELife, 11. https://doi.org/10.7554/ELIFE.71562
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2022 Yasmin Coutinho dos Santos ; Bruno de Almeida Ribeiro; Maria Teresita Del Nino Jesus Fernandez Bendicho; Luana Santana Bacelar; Soane da Silva Félix; Rosa Malena Fagundes Xavier
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
